

# Alfredo AdÃ¡n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1879832/publications.pdf>

Version: 2024-02-01

111  
papers

2,898  
citations

201674

27  
h-index

206112

48  
g-index

113  
all docs

113  
docs citations

113  
times ranked

2572  
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	5.8	197
2	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. <i>Ophthalmology</i> , 2018, 125, 1075-1087.	5.2	134
3	Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 668-675.	5.6	129
4	Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency. <i>American Journal of Ophthalmology</i> , 2014, 158, 1136-1145.e5.	3.3	109
5	Anti-TNF- $\alpha$ therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. <i>Rheumatology</i> , 2014, 53, 2223-2231.	1.9	109
6	Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. <i>Acta Ophthalmologica</i> , 2015, 93, 561-567.	1.1	104
7	Tocilizumab treatment for refractory uveitis-related cystoid macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2627-2632.	1.9	103
8	Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 2183-2188.	2.0	99
9	DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF UVEITIC PERSISTENT CYSTOID MACULAR EDEMA IN VITRECTOMIZED PATIENTS. <i>Retina</i> , 2013, 33, 1435-1440.	1.7	85
10	Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema. <i>Ophthalmology</i> , 2014, 121, 2380-2386.	5.2	83
11	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. <i>American Journal of Ophthalmology</i> , 2019, 200, 85-94.	3.3	81
12	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	5.6	74
13	INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION AS PRIMARY TREATMENT OF INFLAMMATORY CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2007, 27, 1180-1186.	1.7	72
14	Behçet Disease-associated Uveitis Successfully Treated with Golimumab. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 160-162.	1.8	71
15	TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. <i>Retina</i> , 2018, 38, 1361-1370.	1.7	70
16	Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. <i>Scientific Reports</i> , 2016, 6, 22889.	3.3	54
17	Targeting interleukin-6 in autoimmune uveitis. <i>Autoimmunity Reviews</i> , 2017, 16, 1079-1089.	5.8	53
18	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. <i>Ophthalmology</i> , 2018, 125, 1444-1451.	5.2	50

#	ARTICLE	IF	CITATIONS
19	Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. <i>International Ophthalmology</i> , 2010, 30, 577-581.	1.4	42
20	Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis. <i>Human Molecular Genetics</i> , 2018, 27, 4333-4343.	2.9	42
21	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. <i>Frontiers in Immunology</i> , 2018, 9, 808.	4.8	42
22	Certolizumab Pegol, a New Anti-TNF- $\alpha$ in the Armamentarium against Ocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 1-6.	1.8	41
23	Successful Treatment With Infliximab in a Patient With Diffuse Subretinal Fibrosis Syndrome. <i>American Journal of Ophthalmology</i> , 2007, 143, 533-534.	3.3	38
24	Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. <i>European Journal of Ophthalmology</i> , 2009, 19, 1039-1043.	1.3	36
25	Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. <i>American Journal of Ophthalmology</i> , 2016, 161, 172-180.e4.	3.3	31
26	Proinflammatory Cytokines and C-Reactive Protein in Uveitis Associated with Behçet's Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	30
27	Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro. <i>Translational Vision Science and Technology</i> , 2019, 8, 32.	2.2	30
28	Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1873-1875.	1.9	29
29	SAFETY AND EFFICACY OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN THE MANAGEMENT OF MACULAR EDEMA SECONDARY TO INFECTIOUS UVEITIS. <i>Retina</i> , 2016, 36, 1778-1785.	1.7	27
30	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.	5.8	25
31	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. <i>Ophthalmology</i> , 2021, 128, 899-909.	5.2	25
32	Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. <i>PLoS ONE</i> , 2017, 12, e0173865.	2.5	25
33	Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 163-164.	1.9	23
34	Bilateral Acute Retinal Necrosis: Clinical Features and Outcomes in a Multicenter Study. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1090-1098.	1.8	23
35	Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema. <i>Ophthalmology</i> , 2019, 60, 1336.		23
36	Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. <i>PLoS ONE</i> , 2019, 14, e0209997.	2.5	23

#	ARTICLE	IF	CITATIONS
37	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
38	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 1: Diabetic Retinopathy. <i>Translational Vision Science and Technology</i> , 2020, 9, 34.	2.2	22
39	Tocilizumab treatment for recalcitrant uveitic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2249-2250.	1.9	21
40	Interlink between Inflammation and Oxidative Stress in Age-Related Macular Degeneration: Role of Complement Factor H. <i>Biomedicines</i> , 2021, 9, 763.	3.2	21
41	Explantation of intraocular lenses in children with juvenile idiopathic arthritis-associated uveitis. <i>Journal of Cataract and Refractive Surgery</i> , 2009, 35, 603-605.	1.5	20
42	New insights into the genetic component of non-infectious uveitis through an ImmunoChip strategy. <i>Journal of Medical Genetics</i> , 2017, 54, 38-46.	3.2	18
43	Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach. <i>European Journal of Ophthalmology</i> , 2020, 30, 1042-1052.	1.3	18
44	Shear stress modulates inner blood retinal barrier phenotype. <i>Experimental Eye Research</i> , 2019, 187, 107751.	2.6	17
45	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	2.0	17
46	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.8	17
47	Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 425-427.	1.9	16
48	Uveitic macular oedema after treatment with vemurafenib. <i>Acta Ophthalmologica</i> , 2015, 93, e686-7.	1.1	16
49	C-reactive protein isoforms differentially affect outer blood-retinal barrier integrity and function. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 312, C244-C253.	4.6	16
50	Use of Steroids and Heparin to Treat Retinal Arterial Occlusion in Mediterranean Spotted Fever. <i>Journal of Infectious Diseases</i> , 1988, 158, 1139-1140.	4.0	15
51	Challenges in Diabetic Macular Edema Management: An Expert Consensus Report. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 3183-3195.	1.8	15
52	Elevated Serum Immune Mediators and Subclinical Inflammation in HLA-A29-associated Birdshot Chorioretinopathy. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 647-652.	1.8	14
53	Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants. <i>Ophthalmologica</i> , 2018, 240, 61-72.	1.9	14
54	Repeatability and reproducibility of retinal and choroidal thickness measurements in Diabetic Macular Edema using Swept-source Optical Coherence Tomography. <i>PLoS ONE</i> , 2018, 13, e0200819.	2.5	14

#	ARTICLE	IF	CITATIONS
55	CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS. <i>Retina</i> , 2022, 42, 465-475.	1.7	14
56	Interleukin-22 serum levels are elevated in active scleritis. <i>Acta Ophthalmologica</i> , 2016, 94, e395-9.	1.1	13
57	Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study. <i>BMC Ophthalmology</i> , 2018, 18, 179.	1.4	13
58	Multimodal retinal imaging of familial amyloid polyneuropathy. <i>Ophthalmic Genetics</i> , 2019, 40, 407-420.	1.2	13
59	Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. <i>PLoS ONE</i> , 2019, 14, e0210799.	2.5	13
60	Angiography and En Face Optical Coherence Tomography Findings in Acute Syphilitic Posterior Placoid Chorioretinopathy. <i>Case Reports in Ophthalmology</i> , 2019, 10, 165-171.	0.7	12
61	Evaluation of microvascular changes in the perifoveal vascular network using optical coherence tomography angiography (OCTA) in type I diabetes mellitus: a large scale prospective trial. <i>BMC Medical Imaging</i> , 2019, 19, 91.	2.7	12
62	Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro: implications for age-related macular degeneration. <i>Aging</i> , 2020, 12, 13905-13923.	3.1	12
63	Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. <i>European Journal of Ophthalmology</i> , 2009, 19, 1039-43.	1.3	12
64	Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 652-657.	0.8	12
65	Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes. <i>BMC Ophthalmology</i> , 2020, 20, 443.	1.4	10
66	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S40.	0.8	10
67	Clinical Features of Primary and Systemic Metastatic Intraocular Lymphomas in Spanish Patients. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-9.	1.3	9
68	Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN) and Follow-Up Considerations/Recommendations. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 2091-2107.	1.8	9
69	Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes. <i>European Journal of Ophthalmology</i> , 2023, 33, NP23-NP27.	1.3	9
70	Antituberculous Treatment Itself Might Prevent Visual Impairment in Presumed Tuberculosis-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 103-110.	1.8	8
71	Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 228-237.	1.8	8
72	Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema. <i>Frontiers in Immunology</i> , 2020, 11, 579005.	4.8	8

#	ARTICLE	IF	CITATIONS
73	Paracentral acute middle maculopathy after uneventful ocular surgery with local anaesthetic blocks. <i>Eye</i> , 2022, 36, 219-227.	2.1	8
74	Bacillus Calmette-Guérin Infection and Cytotoxicity in the Retinal Pigment Epithelium. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 786-792.	1.8	7
75	Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1203-1210.	1.8	7
76	Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2307-2314.	1.9	7
77	Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 273-278.	1.9	7
78	Tocilizumab for the Treatment of Ocular Inflammatory Disease. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 2-5.	1.8	7
79	Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl- $\beta$ -Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model. <i>Pharmaceutics</i> , 2021, 13, 1737.	4.5	7
80	Clinical Features and Outcomes of Tubulointerstitial Nephritis and Uveitis Syndrome in Spain and Portugal: The IBERTINU Project. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 286-291.	1.8	7
81	An old disease in an atypical place. <i>Survey of Ophthalmology</i> , 2014, 59, 660-663.	4.0	6
82	Specific association of IL17A genetic variants with panuveitis. <i>British Journal of Ophthalmology</i> , 2015, 99, 566-570.	3.9	6
83	Immunostaining images of vitreous transthyretin amyloid. <i>Canadian Journal of Ophthalmology</i> , 2015, 50, 384-387.	0.7	6
84	Recent progress in the treatment of uveitic macular edema. <i>Expert Review of Ophthalmology</i> , 2019, 14, 227-236.	0.6	6
85	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 4: Glycated Haemoglobin. <i>Diagnostics</i> , 2021, 11, 1537.	2.6	6
86	Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 6-8.	1.8	5
87	Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus—Report 2: Diabetic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 197.	2.4	5
88	Cytologic identification of <i>Toxoplasma gondii</i> from subretinal aspirate. <i>Acta Ophthalmologica</i> , 2012, 90, 392-393.	1.1	4
89	Nuevas técnicas de imagen en vasculitis retinianas. <i>Medicina Clínica</i> , 2017, 149, 261-266.	0.6	4
90	Novel Association of High C-Reactive Protein Levels and A69S at Risk Alleles in Wet Age-Related Macular Degeneration Women. <i>Frontiers in Immunology</i> , 2018, 9, 1862.	4.8	4

#	ARTICLE	IF	CITATIONS
91	Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2695-2705.	1.9	4
92	RETROPUPILLARY IRIS-CLAW INTRAOCULAR LENS AND PARS PLANA VITRECTOMY IN APHAKIA MANAGEMENT. Retina, 2021, 41, 2048-2058.	1.7	4
93	Consensus-based recommendations for optical coherence tomography angiography reporting in uveitis. British Journal of Ophthalmology, 2022, , bjophthalmol-2021-320021.	3.9	4
94	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.8	4
95	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. Lupus, 2022, 31, 1344-1354.	1.6	4
96	Optical coherence tomography findings and management of sub-internal limiting membrane haemorrhage. Acta Ophthalmologica, 2008, 86, 582-583.	1.1	3
97	New imaging techniques in retinal vasculitis. Medicina Clínica (English Edition), 2017, 149, 261-266.	0.2	3
98	Presumed tuberculosis-related scleritis. British Journal of Ophthalmology, 2023, 107, 495-499.	3.9	3
99	Biologic drugs in noninfectious uveitis: an update. Expert Review of Ophthalmology, 2013, 8, 501-516.	0.6	2
100	Clinical Course of a Presumed Metastatic Uveal Melanoma to the Contralateral Choroid. Seminars in Ophthalmology, 2015, 30, 417-419.	1.6	2
101	In Response to: "Deuter CM, Zierhut M, Igney-Oertel A, et al. Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment". Ocular Immunology and Inflammation, 2017, 25, 221-222.	1.8	2
102	Estándares de calidad para las Unidades de Atención Integral al paciente con uveítis de la Sociedad Española de Inflammaci3n Ocular (SEIOC). Medicina Clínica, 2021, 156, 76-80.	0.6	2
103	Vogt-Koyanagi-Harada disease in Spain. European Journal of Ophthalmology, 2022, 32, 1547-1554.	1.3	2
104	Spontaneous resolution of inflammatory epiretinal membrane: Case series and review of the literature. European Journal of Ophthalmology, 2023, 33, NP10-NP14.	1.3	2
105	Utility of Ultra-Widefield Retinal Imaging in the Follow-up and Management of Patients with Cytomegalovirus Retinitis. Ocular Immunology and Inflammation, 2020, 28, 659-664.	1.8	1
106	Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. Ocular Immunology and Inflammation, 2021, 29, 1591-1598.	1.8	1
107	Optimization of Diabetic Macular Edema Management in the Real World: A Model of Excellence in Retina Units: The EMUREX Initiative. Ophthalmologica, 2020, 243, 379-390.	1.9	1
108	Ultrawide Field Imaging and OCT Angiography in Late-Onset Chloroquine Retinopathy. Journal of Vitreoretinal Diseases, 2018, 2, 58-60.	0.7	0

#	ARTICLE	IF	CITATIONS
109	RÃ©plica. Medicina ClÃ©nica, 2018, 151, 336-337.	0.6	0
110	THU0573â€¦COMPLICATIONS AND ACTIVITY OF UVEITIS IN A MULTIDISCIPLINARY REFERENCE UNIT IN THE NORTH OF SPAIN. , 2019, , .		0
111	Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography findings. International Ophthalmology, 2021, 41, 787-796.	1.4	0